UNSPSC 51282306: Flurithromycin

This classification denotes a macrolide antibiotic with the molecular formula C37H66FNO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56C9DTE69V, chemically known as erythromycin, 8-fluoro- but generally known as flurithromycin, which bears US NIH Compound Identifier 71260. European Medicines Agency schedules Flurithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07747MIG.

UNSPSC 51282306 Flurithromycin is a Commodity code for a specific antibiotic pharmaceutical product, but the recent state and local opportunities tagged under this code show little direct procurement activity for flurithromycin itself. Instead, the tagged opportunities document purchases of other pharmaceutical products — Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets through a piggyback warehouse contract, and Naloxone plus drug deactivation systems for public health use. State and local health departments, county public health agencies, and emergency preparedness offices are the primary issuing bodies driving pharmaceutical procurement at this code level, typically through cooperative purchasing vehicles (MMCAP Infuse consortium noted in the Illinois example) or competitive IFB processes to secure reliable supplies of medications for emergency response, disease prevention, and community health programs.

The Illinois Department of Public Health awarded a $2,999,999.11 contract over three years to Chartwell Rx LLC on August 28, 2026, via IFB for pharmaceutical warehouse supply of Doxycycline Hyclate and Ciprofloxacin through the MMCAP Infuse piggyback consortium, with initial 12-month term and two renewal years. Seminole County, Florida issued an IFB (solicitation number IFB60459723LAS) with a July 26, 2023 response deadline to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for community health delivery. Recent activity appears concentrated in the Southeast and Midwest, though the mismatch between the flurithromycin code designation and the actual products being purchased suggests either miscoding in the state opportunity database or limited market demand for flurithromycin specifically under this code. Firms pursuing pharmaceutical supply contracts at the state and local level should track cooperative purchasing consortium opportunities and county health department RFQs, where volumes and multiyear terms create material contract value despite the specific commodity code showing limited direct relevant solicitation flow.